You pay to have your DNA tested, and then 23andMe sells the mining rights of those data, and makes royalties on new drugs. 23andMe plans to enter into health care and treat patients. 23andMe aims to expand the use of drugs by getting people on them earlier, before they even have symptoms, based solely on genetic risk factors.

23andMe and Google are linked together through the Wojcicki's sisters. Google came about largely thanks to research grants for mass surveillance technologies from the CIA and the NSA. 23andMe went public after raising more than $1 billion in funding from Google, GlaxoSmithKline, Johnson & Johnson, Sequoia Capital and others.

.Is this a repeat of Google's bait and switch? You pay to have your DNA tested, then this evil company sneakily sells the mining rights of the data and makes royalties on new pharmaceuticals.

STORY AT-A-GLANCE
GlaxoSmithKline (GSK) will pay 23andMe $20 million to extend its five-year contract to mine the company's consumer DNA data for another year
The drugmaker is searching for hints about genes that might be at the root of disease. 23andMe will get royalties on any drugs developed
23andMe also recently launched a new DNA-sequencing service called Total Health, which sequences your entire exome, the protein-coding part of your genome, which is thought to be responsible for most disease-causing genes. The move is another step in 23andMe's plan to transform itself into a full-fledged health care company that also treats patients
23andMe acquired a telehealth and drug-delivery startup called Lemonaid Health in 2021. Lemonaid doctors are being trained by 23andMe on how to interpret DNA results and provide tailored health advice
23andMe's concept of "health care" is all about expanding the use of drugs by getting people on them earlier, before they even have symptoms, based solely on genetic risk factors